American Heart Association (AHA)

The American Heart Association (AHA) funds cardiovascular medical research, educates consumers on healthy living and fosters appropriate cardiac care in an effort to reduce disability and deaths caused by cardiovascular disease and stroke. The AHA also is a key resource for the latest cardiology science through its journals and annual meeting.

Daniel Judge, MD, director of the cardiovascular genetics program, Medical University of South Carolina, the Edwin W. and Teresa H. Rogers Endowed Chair for Cardiovascular Research, Medical University of South Carolina, presented the results of the late-breaking ATTRibute-CM study for the drug acoramidis used to treat transthyretin amyloidosis at AHA 2024.

ATTR-CM drug acoramidis, now approved by the FDA, linked to positive long-term data

Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.

Video of Martha Gulati explaining preventive cardiology advanacements for obese patients. #AHA24 #AHA2024 #CVprev

Martha Gulati highlights 'exciting' progress in preventive cardiology

Martha Gulati, MD, spoke to Cardiovascular Business at AHA Scientific Sessions 2024 about key developments in obesity treatment and CVD prevention.

Left atrial appendage occlusion (LAAO) with the Watchman FLX device from Boston Scientific is associated with positive outcomes and limited adverse events after one year, according to new findings published in Circulation: Cardiovascular Interventions.[1] Many prior Watchman FLX studies, including PINNACLE FLX, had focused on the device’s performance in a controlled setting. The study’s authors hoped to gain a better understanding of its real-world impact by reviewing registry data from more than 97,000 U.S

LAAC with Watchman FLX reduces bleeding risks after AFib ablation

The new data, presented during AHA Scientific Sessions 2024, suggest LAAC with Boston Scientific's Watchman FLX could be a safe, effective alternative to OAC for limiting post-ablation strokes.

Immediate Past President of the American College of Cardiology (ACC) Hadley Wilson, MD, FACC, executive vice chair of Atrium Health Sanger Heart and Vascular Institute and a clinical professor of medicine at Wake Forest University School of Medicine, details the top late-breaking studies at AHA 2024. #AHA24 #AHA2024

9 key takeaways from AHA 2024 in Chicago

Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.

artificial intelligence in cardiology

No-contact blood pressure and diabetes screening with AI shows promise

The new technology, still under development, could help physicians screen patients for diabetes and hypertension with high-speed video recordings. 

Philippe Genereux explains how EARLY TAVR will help raise awareness for undertreatment of TAVR.

New data put a spotlight on troubling TAVR trends

Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, noted that many patients with severe AS still go untreated.

The entrance to the AHA expo and technology floor. #AHA22

American Heart Association announces late-breaking research for Scientific Sessions 2024

The three-day conference begins Saturday, Nov. 16, in Chicago. Topics will include AI, heart failure, patient management and much more. 

Overview of the pathophysiological mechanisms associated with arrhythmogenesis in the setting of COVID-19 infection. Image from Circulation.

AHA issues a scientific statement on COVID-19 cardiac arrhythmias

The objective of the AHA scientific statement is to review the available evidence on for better management of cardiac arrhythmias from COVID causes that are still encountered on a regular basis.